Jacobs Levy Equity Management’s NovoCure NVCR Stock Holding History

Jacobs Levy Equity Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.6M	Sell	1,164,072 -167,420	-13%	-$2.53M	0.06%	240
2026 Q1	$14.5M	Buy	1,331,492 +107,737	+9%	+$1.35M	0.06%	255
2025 Q4	$15.8M	Buy	1,223,755 +1,121,192	+1,093%	+$14.4M	0.06%	242
2025 Q3	$1.33M	Sell	102,563 -45,638	-31%	-$610K	0.01%	666
2025 Q2	$2.64M	Buy	+148,201	New	+$2.58M	0.01%	566
2024 Q2	–	Sell	-475,226	Closed	-$7.43M	–	1018
2024 Q1	$7.43M	Buy	475,226 +358,062	+306%	+$5.27M	0.03%	356
2023 Q4	$1.75M	Buy	117,164 +95,202	+433%	+$1.27M	0.01%	619
2023 Q3	$355K	Buy	+21,962	New	+$633K	﹤0.01%	860
2021 Q2	–	Sell	-209,211	Closed	-$27.7M	–	1090
2021 Q1	$27.7M	Buy	209,211 +27,209	+15%	+$4.3M	0.21%	126
2020 Q4	$31.5M	Buy	182,002 +105,892	+139%	+$14.5M	0.28%	93
2020 Q3	$8.47M	Sell	76,110 -9,990	-12%	-$799K	0.09%	242
2020 Q2	$5.11M	Buy	86,100 +37,245	+76%	+$2.45M	0.06%	328
2020 Q1	$3.29M	Sell	48,855 -1,035	-2%	-$81.8K	0.04%	373
2019 Q4	$4.2M	Sell	49,890 -36,443	-42%	-$2.94M	0.04%	408
2019 Q3	$6.46M	Sell	86,333 -19,290	-18%	-$1.54M	0.08%	293
2019 Q2	$6.68M	Buy	105,623 +190	+0.2%	+$9.63K	0.09%	278
2019 Q1	$5.08M	Buy	105,433 +17,970	+21%	+$865K	0.07%	328
2018 Q4	$2.93M	Buy	87,463 +4,364	+5%	+$160K	0.05%	373
2018 Q3	$4.35M	Buy	83,099 +44,569	+116%	+$1.77M	0.06%	344
2018 Q2	$1.21M	Buy	+38,530	New	+$1.07M	0.02%	616

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Jacobs Levy Equity Management's NVCR Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its NovoCure (NVCR) stake by 13% in Q2 2026, selling an estimated $2.53M and leaving 1,164,072 shares worth $17.6M. The position accounts for 0.06% of the portfolio, ranked #240.

Jacobs Levy Equity Management first reported a position in NVCR in Q2 2018 and has held it in 20 quarters since. The position peaked at $31.5M in Q4 2020. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Jacobs Levy Equity Management held 1,164,072 shares of NovoCure worth $17.6M as of Q2 2026.
Jacobs Levy Equity Management sold 167,420 NovoCure shares in Q2 2026, an estimated $2.53M.
NovoCure made up 0.06% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #240 holding.
Jacobs Levy Equity Management first reported a position in NovoCure in Q2 2018 and has held it in 20 quarters since.
Jacobs Levy Equity Management's NovoCure position peaked at $31.5M in Q4 2020.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.